Study of Compound Nanxing Zhitong Ointment in the Treatment of Chronic Pain in Musculoskeletal System
CompletedNCT07200362
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
A prospective cohort study on the treatment of chronic pain in the musculoskeletal system with Compound Nanxing Pain Relief Ointment. This study adopted an observational research design. Through a cohort study, patient medical records were collected to meet the criteria of chronic pain classification in International Classification of Diseases 11th Revision (ICD-11), which is located in the musculoskeletal system and occurs in the neck and shoulders, waist and back, limbs, and meets the diagnostic criteria of "cold syndrome" in traditional Chinese medicine. The target population was selected to evaluate the clinical effects of Compound Nanxing Pain Relief Ointment in treating chronic pain in the musculoskeletal system, reducing pain, improving muscle and bone function status, and enhancing quality of life. The study aimed to compare the heterogeneity of the clinical effects of Compound Nanxing Pain Relief Ointment in treating chronic pain in the musculoskeletal system. The study plan included 3000 patients, and no intervention in treatment and medication was provided to the patients during the observation period. The shortest medication duration was 2 weeks, and the longest observation period was 3 months.
Study details
- Official title
- A Prospective Cohort Study of Compound Nanxing Zhitong Ointment in the Treatment of Chronic Pain in the Musculoskeletal System
- Conditions
- Chronic Primary Musculoskeletal Pain
- Interventions
- Drug: Compound Nanying zhitong Ointment
- Other: Do not use any other similar proprietary medicines or traditional Chinese medicines.
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
- Start date
- 2021-10-30
- Primary completion
- 2023-06-14
- Sex
- All
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: For those who visit the orthopedics department, rheumatology department, or pain clinic: 1. Those whose pain is located in the musculoskeletal system as classified in International Classification of Diseases 11th Revision(ICD-11) for chronic pain, and occurs in the neck, shoulders, waist, back, or limbs; 2. Those who meet the diagnostic criteria of "cold syndrome" in traditional Chinese medicine, and their chronic pain worsens or occurs when exposed to cold; 3. Those with continuous or intermittent pain lasting more than 3 months, and without surgical indications. Exclusion Criteria: None
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07200362